Bioreclamation Group, Inc. announced it has acquired Celsis In Vitro Technologies (“CelsisIVT”), a division of Celsis International Ltd. and a provider of in vitro products for the study of drug metabolism and toxicity. Brown Gibbons Lang & Company represented the Maryland-based CelsisIVT in the transaction. Terms of the deal were not disclosed.
The two companies will combine to become BioreclamationIVT, creating a one-stop shop offering a complete range of biological tools needed to pursue new drug discovery and development. The combined Companies’ highly specialized products enable researchers to better understand the pharmacokinetics and metabolism of newly discovered compounds. BioreclamationIVT’s sophisticated sourcing and exceptional quality control processes help reduce the time and cost of screening drug compounds in early-stage drug discovery and development.